The economic impact and variability of managing distal renal tubular acidosis (dRTA) in the UK healthcare setting

Previous PostNegative reimbursement decisions and a review of methods to drive positive reimbursed status
Next PostThe economic impact and variability of managing non-tuberculous mycrobacterial lung disease in the UK healthcare setting